Hiru Corporation  (HIRU)   Hiru Corporation is a parent company of China based pharmacutical company - Jiang Xi Rongyu Pharmacutical Group, Inc.  Hiru opens its way to become a multinational player with substantial operations and revenues. Jiang Xi Rongyu Pharmacutical Group, Inc. strong and strategically-balanced Pharmacutical Co with plans to enter international trade markets, expand and deliver the expanding product lines worldwide. Company main focus is on the production of Chinese traditional naturopathic medicine facility consisting of 60 acres of production fields (approx. 25 hectares) and over 5000 hectares of a neighboring mountain outside Fuzhou City, Jiangxi Province.

Recent Price $.10 Market Capitalization $97 M Est. Float 95.8 Outstanding Shares 675 M Exchange OTC.PK Hiru Corp. 375 N. Stephanie St Suite 1411 Henderson, NV 89014 http://www.hirucorporation.com

Similar Companies in Sector Javo Beverage Company, Inc. (Javo) manufactures and sells concentrated beverage solutions that allow restaurants in the food service industry, and food and beverage manufacturers in the retail industry to serve specialty coffees and teas. For food and beverage processors, and retailers looking for coffee and tea flavors for their packaged foods and ready-to-drink beverages, Javo supplies customized beverage formulations, extracts and flavors .   OTCBB: JAVO Recent Price: $.185   Peet's Coffee & Tea, Inc. (Peet's) is a specialty coffee roaster and marketer of fresh roasted whole bean coffee. The Company sells its coffee through multiple channels of distribution, including grocery stores, home delivery, office, restaurant and food service accounts, and Company-owned and operated stores in six states. The Company operates its business through two segments: retail and specialty sales, which consist of sales to home delivery customers, sales to grocery stores, restaurant and food service companies, and office accounts. NASDAQ: PEET Recent Price: $34.21

Hiru Corporation (HIRU) to Announces 5-1 Forward Stock Split Ahead of (HTDS) Distribution Hiru Corporation Recently announced that its Board of Directors and shareholders have approved a five-for-one forward split (5-1) of the Company's common stock and certain other actions. In order to receive new shares, the shareholders will have to tender the old shares to the transfer agent. The record and effective dates for this split will be set with the assistance of FINRA, the Financial Industry Regulatory Authority. This process may take up to four weeks. Shareholders will be notified in advance when this occurs and need not take any action now. Certain anti-takeover provisions also have been added to the Articles of Incorporation. Under our agreement with Hard To Treat Diseases this will affect the HTDS payout from 40 million shares to about 200 million shares to HTDS and its shareholders representing the purchase of the MindUp Bio Research Division.

Hiru Corporation's (HIRU) Medicine Added to the 'National Essential Drug List' Hiru Corporation and its subsidiary Jiangxi RongYu Pharmaceutical Group, Inc. recently announced that one of the company's products has been officially added onto the National Essential Drugs List. Jiangxi Leading Group Office issued an ordinance of qualified candidates for the 'National Essential Drug List'; and Jiangxi RongYu product, the 'Yuan Hu Zhi Tong Capsule' had been added to this List. As by the decree of the Ministries of Finance and of Health, all medicines placed on this list must be available to doctors and in stock with pharmacies and county hospitals. The government health plan also fully covers and reimburses the patients for the use of this medicine. Being placed on this list and the fact that the medical authorities are required by law to carry this medicine increases Jiangxi RongYu Pharmaceutical Group's sales and marketing efficiency, while significantly reducing marketing and distribution costs for this product. 'Yuan Hu Zhi Tong Capsule' or 'Yuan Hu Zhi Tong Pian' is a traditional formula for alleviating pain, including headaches, menstrual discomfort, liver or gallbladder problems, angina and muscle spasms.

Company Profile Hiru Corporation  (HIRU) Hiru Corporation is a parent company of China based pharmacutical company - Jiang Xi Rongyu Pharmacutical Group, Inc. (http://www.jxrongyuyy.com), Hiru opens its way to become a multinational player with substantial operations and revenues. Jiang Xi Rongyu Pharmacutical Group, Inc. (http://www.jxrongyuyy.com/) is strong and strategically-balanced Pharmacutical Co with plans to enter international trade markets, expand and deliver the expanding product lines worldwide. Company main focus is on the production of Chinese traditional naturopathic medicine facility consisting of 60 acres of production fields (approx. 25 hectares) and over 5000 hectares of a neighboring mountain outside Fuzhou City, Jiangxi Province. The production factory of over 14 000 square meters employs 460 people and a healthy and growing annual production capacity, The Company earned National 'Good Manufacturing Practice' certificate in 2006, and is the largest 'Good Agricultural Practice' plant in Jiangxi Province. The company also operates a RD lab in Belgrade Serbia MindUp Bioresearch focusing on cancer therapy and alternative medicine. Jiangxi RongYu Pharmaceutical Group Co., Ltd. focuses on the production of traditional Chinese naturopathic medicines outside Fuzhou City, China. The company's modern facility and technology earned national GMP (Good Manufacturing Practice) certificate in 2006, and its sustainable agricultural approach earned the company GAP (Good Agricultural Practice) certificate. The company is the largest in Jiangxi Province to hold the GAP certificate. Jiangxi RongYu Pharmaceutical Group Co., Ltd. also earned awards such as "Outstanding Entrepreneur of China", "Excellent Private Enterprise" and earned a nomination for the "Top Ten Employers in Jiangxi Province". Jiangxi RongYu Pharmaceutical Group Co., Ltd.'s modern, state-of-the-art facility of over 14, 000 square meters, employs 460 experienced workers. The annual production capacity of the facility is 300 million tablets, 200 million capsules, 260 tons of grain and 120 tons of Chinese Herbal Pieces. The company's production grounds cover area of more than 60 acres (approx. 25 hectares) and the company signed a 50-year lease for 7.2 hectares of a mountain in Linchuan. Jiangxi RongYu Pharmaceutical Group Co., Ltd. cultivates plants and develops curatives that had been used as a vital a part of Chinese traditional medicine for centuries and had endured the trial of time. Our scientific processing methods and rigorous quality control set our herbs apart from other sources of Chinese herbs. The main medicinal herbs we produce include Yuan Hu, Angelica, Jujube, Gingko, Evodia, Eucommia, and Southernwood. Products Jiangxi RongYu Pharmaceutical Group Co., Ltd. focuses its products on the treatment of gynecological and liver conditions and imbalances. The company also develops new products and new dosage approaches in herbal medicine. All products obtained the state-level medical registration for distribution of these curatives. With the goal to deliver its top products to the market and improve the health and well-being of the Chinese population, the company uses both, sustainable approaches for cultivation and modern technology for economical and ecological production of these traditional curatives. Notice: Even all of company's products are herbal preparations, the patients should not take lightly the effect of these products. The products of Jiangxi RongYu Pharmaceutical Group Co., Ltd. do not intend to replace professional medical advice or treatment. Individual results may vary, and Jiangxi RongYu Pharmaceutical Group Co., Ltd. urges you to seek the advice of a qualified professional for any lasting health concerns, and to share with your healthcare provider any information relevant to your health and well-being, including the use of herbal supplements. Leadership Rongyu Ye, CEO Company Officers Rongyu Ye, CEO Carol Robichaud, Secretary Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Dr. Mirjana Stojiljkovic, Director, New Projects, Chief Scientist Dr. Sabera Ruzdijic, Medical Director Dr. Milica Pesicand, Medical Director Dr. Jasna Bankovic, Medical Director Dr. Nikola Tanic, Medical Director Dr. Ivana Gadjanski, Director, Comm. Number of Employees 86 as of Dec 29, 2009

PLEASE NOTE: First Alert Stocks and/or its affiliates are not registered as Investment Advisors in any jurisdiction whatsoever.

Release of Liability: Through use of First Alert Stocks email newsletters and website you agree to hold First Alert Stocks, its operators, owners, and employees harmless and completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. First Alert Stocks The owner, publisher, editor and their associates are not responsible for errors and omissions. First Alert Stocks and/or its affiliates may from time to time have positions in the securities mentioned herein, may increase or decrease such positions without notice, and may profit from such transactions. First Alert Stocks encourages readers and investors to supplement the information in these reports with independent research and other professional advice.

Privacy Statement

Discover the Secrets to
"Investing in Stocks"

Free Trader EBook Library

Master Your Trading Mindtraps

Tips and Tricks For a Trader to Make the Market Work For You

When To Sell Stocks